Abstract
The spondin-2 correlated with tumor progression in many malignancies. However, the role of spondin-2 in gastric cancer has not been thoroughly elucidated. Spondin-2 and matrix metallopeptidase 9 (MMP-9) expression was detected by immunohistochemistry in 174 gastric carcinoma tissues. The relationship between the expression of spondin-2 and MMP-9, clinicopathological/prognostic value in gastric cancer was examined. Spondin-2 was significantly higher in gastric cancer than that in adjacent non-tumorous tissues. Spondin-2 overexpression was significantly associated with well differentiation, depth of invasion, lymph node metastasis, and advanced TNM stages. The expression levels of spondin-2 were increasing in both prominent serosal invasion group and lymph node metastasis group. In addition, spondin-2 was positively correlated with MMP-9 among 174 gastric cancer samples. In univariate and multivariate analyses, spondin-2 was an independent prognostic factor for both recurrence-free survival (RFS) and overall survival (OS). Moreover, spondin-2 overexpression was associated with poor prognosis in patients with gastric cancer in different risk groups. In conclusion, Spondin-2 overexpression contributes to tumor aggressiveness and prognosis, and could be a promising target for prognostic prediction in gastric cancer patients.
Highlights
Gastric cancer is an aggressively invasive tumor, and one of the most common lethal cancers worldwide [1, 2]
To investigate the biological significance of Spondin-2 in gastric cancer, we detected the expression of Spondin-2 in 174 gastric cancer tissues by immunohistochemistry
The results suggested that Spondin-2 expression was significantly higher in gastric cancer than that in adjacent non-tumorous tissues
Summary
Gastric cancer is an aggressively invasive tumor, and one of the most common lethal cancers worldwide [1, 2]. The incidence of gastric cancer in China and some East Asia countries is much higher than that in America or Europe countries [3]. Surgical resection may successfully treat gastric cancer in the early stage of disease [4]. Due to atypical symptoms at the early stage, over 80% of patients with gastric cancer were diagnosed at an advanced stage, which usually indicates a poor prognosis [5]. Increasing numbers of biomarkers have been reported that are associated with different types of cancer [6]. The identification of novel biomarkers to predict prognosis is important to guide the treatment of patients with gastric cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
